The University of Colorado

The University of Colorado

The University of Colorado

Overview
Date Founded

1876

Headquarters

Campus Box 30,Boulder, CO 80309

Employees (Worldwide)

10K - 1M

Industries

Schools & Student Services

Company Description

The University of Colorado advances the economy, health and culture of Colorado and beyond, educating more than 435,000 students who have become catalysts in business, arts, health, and community growth. CU's four campuses feature top-tier faculty and hands-on learning opportunities in an environment where students thrive.

Contact Data
Trying to get in touch with decision makers at The University of Colorado? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President

Chief Scientific Officer & Professor

Chairman-Pediatrics Department

Professor & Head-BioEngineering Department

Advocacy Director

Faculty Director

Director-Atlas Institute

Director-Center for Information Technology

Associate Professor of Law, Director, Silicon Flatirons Center for Law & Technology

Managing Director, Entrepreneurship, Innovation & Design

Board of Directors

Limited Partner at Carlisle Enterprises LLC

Chief Executive Officer at Rexam Beverage Can Co.

Operating Partner, Defense, Telecom & Semiconductors at Five Crowns Capital LLC

Former President & Chief Executive Officer at TearSolutions, Inc.

Distinguished Alumni
E. Scott Santi is now Chairman & Chief Executive Officer at Illinois Tool Works, Inc.
Ted Waitt is now Founder & Chairman at Waitt Family Foundation
Richard M. Burridge, Sr. is now Chief Executive & Investment Officer at RMB Capital Holdings LLC
Paths to The University of Colorado
Potential Connections via
Relationship Science
You
The University of Colorado
Advisors & Consultants
Legal Advisor

Founding Member at Haddon, Morgan & Foreman PC

Consultant

Vice President at Grenzebach Glier & Associates, Inc.

Advisor

Technology Director at ACF Solutions LLC

Clients

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Nurse-Family Partnership provides maternal and childhood health services. The firm helps women engage in preventive health practices, including getting prenatal care from their healthcare providers, improving their diet, and reducing use of cigarettes, alcohol, and illegal substances. The company is headquartered in Denver, CO.

Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
$100
12/31/2019
$1,000
12/31/2019
$18.4K
07/31/2019
Investments
Details Hidden

Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA.

Details Hidden

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Awards & Honors
Rank #147
2010
The Chronicle of Philanthropy - Philanthropy 400
Rank #127
2009
The Chronicle of Philanthropy - Philanthropy 400
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by The University of Colorado. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of The University of Colorado's profile does not indicate a business or promotional relationship of any kind between RelSci and The University of Colorado.